Gilead Science (GILD.US), a US biotech company gains over 10% at the start of the Wall Street session, based on information about the possible high efficacy of Remdesivir drug for coronavirus. The drug was previously used to treat other viruses, such as Eboli or SARS or MERS. According to the company, the drug is expected to significantly weaken the effect of coronavirus and lead to faster recovery of patients. Attempts to treat people infected with coronavirus with Remdesivir have been conducted on a small sample and involved people with rather mild symptoms, so scientists are asking to refrain from euphoria regarding the effectiveness of this drug.

Gilead is opening up with a large bullish gap. Source: xStation5
Morning Wrap: US Indices rise ahead of CPI and Fed Chair Warsh speech (14.07.2026)
US OPEN: Capital is once again fleeing “memory stocks”; Wall Street under pressure at the open 🚨
Market Wrap: Geopolitical déjà vu. Hormuz once again in the center of investors' attention.
Morning Wrap: Strait of Hormuz Closed? (13.07.2026)